16,887 Shares in Repligen Corporation (NASDAQ:RGEN) Acquired by Bank of Nova Scotia

Bank of Nova Scotia bought a new position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,887 shares of the biotechnology company's stock, valued at approximately $2,149,000.

A number of other hedge funds also recently made changes to their positions in the stock. PNC Financial Services Group Inc. increased its stake in Repligen by 4.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,632 shares of the biotechnology company's stock worth $462,000 after buying an additional 152 shares during the period. Blueshift Asset Management LLC acquired a new position in Repligen during the 1st quarter valued at about $458,000. Commerce Bank boosted its stake in Repligen by 7.5% during the 1st quarter. Commerce Bank now owns 1,899 shares of the biotechnology company's stock valued at $242,000 after purchasing an additional 133 shares during the period. US Bancorp DE lifted its stake in shares of Repligen by 4.0% in the 1st quarter. US Bancorp DE now owns 10,628 shares of the biotechnology company's stock worth $1,352,000 after acquiring an additional 406 shares during the period. Finally, Nicolet Advisory Services LLC lifted its stake in Repligen by 10.6% during the first quarter. Nicolet Advisory Services LLC now owns 3,607 shares of the biotechnology company's stock valued at $459,000 after purchasing an additional 345 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Repligen Price Performance

Shares of NASDAQ:RGEN traded down $2.09 during midday trading on Friday, reaching $111.43. 635,942 shares of the company's stock were exchanged, compared to its average volume of 1,059,227. The company's 50 day simple moving average is $122.76 and its two-hundred day simple moving average is $134.58. The firm has a market capitalization of $6.26 billion, a PE ratio of -445.70, a price-to-earnings-growth ratio of 2.09 and a beta of 1.05. Repligen Corporation has a 12 month low of $102.96 and a 12 month high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.65% and a negative net margin of 2.05%. The company's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter last year, the business earned $0.40 EPS. Equities research analysts expect that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on RGEN shares. Canaccord Genuity Group cut their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a report on Wednesday, April 16th. Wells Fargo & Company dropped their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Evercore ISI lowered their target price on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating on the stock in a research note on Tuesday, July 8th. Wall Street Zen lowered shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price on the stock in a research note on Tuesday, April 29th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $169.45.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.